Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27–45 years, compared with catch-up through age 26 years and 21 years for females and males, respecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Vincent, Prabhu, Vimalanand S., Palmer, Cody, Samant, Salome, Kothari, Smita, Roberts, Craig, Elbasha, Elamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189092/
https://www.ncbi.nlm.nih.gov/pubmed/33427033
http://dx.doi.org/10.1080/21645515.2020.1852870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189092/
https://www.ncbi.nlm.nih.gov/pubmed/33427033
http://dx.doi.org/10.1080/21645515.2020.1852870

Ejemplares similares